Inxight Drugs

U.S. Department of Health & Human Services Divider Arrow

National Institutes of Health Divider Arrow

NCATS

Return Home Inxight Drugs

Home
Browse Drugs
Search
- Structure Search
- Sequence Search
Downloads
About

Show Filters

Hide Filters

Development Status

Other

1

Possibly Marketed Outside US

1

All Match

Any Match

Exclude Selected

Exclude Selected

Approval Year

2001

1

Unknown

1

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Class

Concept

1

Structurally Diverse

1

All Match

Any Match

Exclude Selected

Exclude Selected

Code System

FDA ORPHAN DRUG

2

NDF-RT

2

DAILYMED

1

DRUG BANK

1

EVMPD

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 1

ANTIINFECTIVES FOR SYSTEMIC USE

1

VARIOUS

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 2

ALL OTHER THERAPEUTIC PRODUCTS

1

VACCINES

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 3

ALL OTHER THERAPEUTIC PRODUCTS

1

BACTERIAL VACCINES

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 4

Antidotes

1

Tuberculosis vaccines

1

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Form

Principal Form

1

All Match

Any Match

Exclude Selected

Exclude Selected

Search results for "ORPHAN DRUG|Designated|Treatment of severe preeclampsia and eclampsia" in comments (approximate match)

Showing 1 - 2 of 2 results

First page disabled
Previous page disabled
1
Next page disabled
Next page disabled

OVINE DIGOXIN IMMUNE FAB

YB12NQZ1YN

Status:

Possibly Marketed Outside US

First approved in 2001

Class:

STRUCTURALLY DIVERSE

DIGOXIN IMMUNE FAB (OVINE)

YB12NQZ1YN

Status:

Other

Class:

CONCEPT

HHS VULNERABILITY DISCLOSURE

For language access assistance, contact the NCATS Public Information Officer

National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966


			version 1.1